Literature DB >> 6365739

Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention.

H Moser.   

Abstract

Duchenne muscular dystrophy (DMD) is the most common sex linked lethal disease in man (one case in about 4000 male live births). The patients are wheelchair bound around the age of 8-10 years and usually die before the age of 20 years. The mutation rate, estimated by different methods and from different population studies, is in the order of 7 X 10(-5), which is higher than for any other X-linked genetic disease. Moreover, unlike other X linked diseases such as hemophilia A or Lesh-Nyhan's disease, there seems to be no sex difference for the mutation rates in DMD. Several observations of DMD in girls bearing X-autosomal translocations and linkage studies on two X chromosomal DNA restriction fragment length polymorphisms indicate that the DMD locus is situated on the short arm of the X chromosome, between Xp11 and Xp22. It may be of considerable length, and perhaps consisting of actively coding and non-active intervening DNA sequences. Thus unequal crossing over during meiosis in females could theoretically account for a considerable proportion of new mutations. However, there is no structurally or functionally abnormal protein known that might represent the primary gene product, nor has any pathogenetic mechanism leading to the observed biochemical and histological alterations been elucidated. Among the numerous pathogenetic concepts the hypothesis of a structural or/and functional defect of the muscular plasma membrane is still the most attractive. It would explain both the excess of muscular constituents found in serum of patients and carriers, such as creatine kinase (CK), as well as the excessive calcium uptake by dystrophic muscle fibres, which, prior to necrosis, could lead to hypercontraction, rupture of myofilaments in adjacent sarcomeres and by excessive Ca uptake to mitochondrial damage causing crucial energy loss. The results of studies on structural and functional membrane abnormalities in cells other than muscle tissue, e.g., erythrocytes, lymphocytes and cultured fibroblasts, indicate that the DMD mutation is probably demonstrable in these tissues. However, most of the findings are still difficult to reproduce or even controversial. DMD is an incurable disease; therefore most effort, in research as well as in practical medicine, is concentrated upon its prevention.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6365739     DOI: 10.1007/bf00275183

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  366 in total

1.  On Granular and Fatty Degeneration of the Voluntary Muscles.

Authors:  E Meryon
Journal:  Med Chir Trans       Date:  1852

2.  Membrane abnormalities in Duchenne muscular dystrophy.

Authors:  G E Jones; J A Witkowski
Journal:  J Neurol Sci       Date:  1983-02       Impact factor: 3.181

3.  Mitochondrial calcium overload: A general mechanism for cell-necrosis in muscle diseases.

Authors:  K Wrogemann; S D Pena
Journal:  Lancet       Date:  1976-03-27       Impact factor: 79.321

4.  Duchenne muscular dystrophy: plasma membrane loss initiates muscle cell necrosis unless it is repaired.

Authors:  S Carpenter; G Karpati
Journal:  Brain       Date:  1979-03       Impact factor: 13.501

5.  Normality of erythrocyte phospholipids in Duchenne muscular dystrophy.

Authors:  C L Koski; F B Jungalwala; E H Kolodny
Journal:  Clin Chim Acta       Date:  1978-05-02       Impact factor: 3.786

6.  Chemical compositional studies of erythrocyte membranes in Duchenne muscular dystrophy.

Authors:  D V Godin; M A Bridges; P J MacLeod
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1978-05

Review 7.  Role of intracellular calcium in promoting muscle damage: a strategy for controlling the dystrophic condition.

Authors:  C J Duncan
Journal:  Experientia       Date:  1978-12-15

8.  Capping of lymphocytes for carrier detection in Duchenne muscular dystrophy: technical problems and a review of the literature.

Authors:  A D Ho; B Reitter; S Stojakowits; W Fiehn; J Weisser
Journal:  Eur J Pediatr       Date:  1980-09       Impact factor: 3.183

9.  Erythrocyte spectrofluorometric abnormalities in Duchenne patients and carriers. A new approach to carrier detection.

Authors:  G Scarlato; G Meola; V Silani; L Manfredi; G Bottiroli; A Zanella
Journal:  Acta Neurol Scand       Date:  1979-05       Impact factor: 3.209

10.  [Screening for elevated creatine kinase activities for the early diagnosis of Duchenne muscular dystrophy].

Authors:  R Beckmann; G Scheuerbrandt
Journal:  Fortschr Med       Date:  1979-10-18
View more
  108 in total

1.  Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old.

Authors:  G S Lynch; R T Hinkle; J S Chamberlain; S V Brooks; J A Faulkner
Journal:  J Physiol       Date:  2001-09-01       Impact factor: 5.182

2.  Long-term engraftment of multipotent mesenchymal stromal cells that differentiate to form myogenic cells in dogs with Duchenne muscular dystrophy.

Authors:  Yuko Nitahara-Kasahara; Hiromi Hayashita-Kinoh; Sachiko Ohshima-Hosoyama; Hironori Okada; Michiko Wada-Maeda; Akinori Nakamura; Takashi Okada; Shin'ichi Takeda
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

3.  Resting calcium concentrations in isolated skeletal muscle fibres of dystrophic mice.

Authors:  D A Williams; S I Head; A J Bakker; D G Stephenson
Journal:  J Physiol       Date:  1990-09       Impact factor: 5.182

4.  Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy.

Authors:  Noah Weisleder; Norio Takizawa; Peihui Lin; Xianhua Wang; Chunmei Cao; Yan Zhang; Tao Tan; Christopher Ferrante; Hua Zhu; Pin-Jung Chen; Rosalie Yan; Matthew Sterling; Xiaoli Zhao; Moonsun Hwang; Miyuki Takeshima; Chuanxi Cai; Heping Cheng; Hiroshi Takeshima; Rui-Ping Xiao; Jianjie Ma
Journal:  Sci Transl Med       Date:  2012-06-20       Impact factor: 17.956

5.  Screening for Duchenne muscular dystrophy.

Authors:  R A Smith; M Rogers; D M Bradley; J R Sibert; P S Harper
Journal:  Arch Dis Child       Date:  1989-07       Impact factor: 3.791

Review 6.  Improved diagnosis of Duchenne/Becker muscular dystrophy.

Authors:  A H Beggs; L M Kunkel
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

7.  Intragenic deletions in 21 Duchenne muscular dystrophy (DMD)/Becker muscular dystrophy (BMD) families studied with the dystrophin cDNA: location of breakpoints on HindIII and BglII exon-containing fragment maps, meiotic and mitotic origin of the mutations.

Authors:  B T Darras; P Blattner; J F Harper; A J Spiro; S Alter; U Francke
Journal:  Am J Hum Genet       Date:  1988-11       Impact factor: 11.025

8.  A novel product of the Duchenne muscular dystrophy gene which greatly differs from the known isoforms in its structure and tissue distribution.

Authors:  S Bar; E Barnea; Z Levy; S Neuman; D Yaffe; U Nudel
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

9.  Heterozygotic gene expression in endomyocardial biopsies: a new diagnostic tool confirms the Duchenne carrier status.

Authors:  M Schmidt-Achert; P Fischer; W Müller-Felber; H Mudra; D Pongratz
Journal:  Clin Investig       Date:  1993-03

10.  Left ventricular T2 distribution in Duchenne muscular dystrophy.

Authors:  Janaka P Wansapura; Kan N Hor; Wojciech Mazur; Robert Fleck; Sean Hagenbuch; D Woodrow Benson; William M Gottliebson
Journal:  J Cardiovasc Magn Reson       Date:  2010-03-18       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.